In the pooled analysis, once-daily 15- to 20-mg doses of rivaroxaban were significantly associated with a higher intracranial hemorrhage risk compared with aspirin.
One in 8 patients with ACI experience ultra-early neurological deterioration during ambulance transport and initial evaluation at the emergency department.
A team of investigators sought to assess the efficacy and safety of cilostazol vs aspirin, both with and without probucol, a cholesterol-lowering agent, in Asian patients with ischemic stroke.
Only patients transported via EMS were enrolled, suggesting that these findings are limited to those with more severe blunt head injury vs those who self-present to the emergency department.
Although spot sign predicted ICH expansion, it proved to be a less robust diagnostic marker than demonstrated by previous single-center cohort studies.
Risk for symptomatic intracranial hemorrhage after endovascular treatment for acute ischemic stroke is significantly higher in real-world practice than rates reported by clinical trials.
Compared with other sources of ICH, those associated with arteriovenous malformations had lower odds of death.
Intracranial atherosclerosis was lower in patients with migraine compared with those without migraine.
Patients receiving treatment with vitamin K antagonists (VKA) or antiplatelet agents face a significantly increased risk of mortality within 24 hours of intracranial hemorrhage.
Concomitant use of oral anticoagulants contributed to a significantly higher increased risk for ICH.
The idea of low-dose tPA will likely not be abandoned despite recent findings.
Risk factors differ from ischemic stroke.
REVERSE-AD is an ongoing phase 3 cohort study evaluating the reversal effects of idarucizumab on dabigatran.
Treatment with IV tPA appeared safe and feasible with stroke onset confirmation from MRI.
Surprisingly, multiple types of stroke were associated with a greater risk of seizure than TBI.
Patients with symptoms of TIA should undergo brain imaging to rule out ICH prior to antithrombotic therapy.
The study did not establish whether early intervention improves outcomes.
Compared to standard treatment with IV tPA, endovascular thrombectomy resulted in better functional outcomes at 90 days.
Treatment of intracerebral hemorrhage after thrombolysis did not result in reduced mortality or expansion of the hematoma.
A simple blood test may indicate risk of intracerebral hemorrhage and post-stroke outcomes.
NOACs are prescribed to patients with lower stroke risk compared to those prescribed Warfarin.
Those treated with a stent were twice as likely to suffer a stroke or transient ischemic attack compared to those treated with medication alone.
Those taking dabigatran (Pradaxa) had higher risk of major bleeds, including gastrointestinal bleeding.
Neurology Advisor Articles
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Patients With Multiple Sclerosis Face Greater Infection Risk
- Fingolimod Compared With Glatiramer Acetate in Head-to-Head MS Study
- Lower Relapse Risk and Disability Progression With Oral DMT in Treatment-Naive RRMS
- Anodal tDCS Offers Possible Benefit for Improving Item Recall in Post-Stroke Aphasia
- Hospitalization Tied to Brain Abnormalities in Older Adults
- Spending Often Persists in High-Cost Medicare-Medicaid Eligible
- Skills-Based Intervention Did Not Cut Systolic BP After Stroke, TIA
- High Frequency of Headaches Following Dialysis Associated With BUN and Blood Pressure